• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/24/24 1:35:24 PM ET
    $ABBV
    $BMY
    $HCA
    $IOVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PFE CALL SWEEP BULLISH 05/31/24 $29.00 $50.3K 6.8K 8.2K
    SRPT CALL TRADE BULLISH 06/21/24 $110.00 $1.3 million 211 1.0K
    NVAX CALL SWEEP BEARISH 07/19/24 $22.50 $35.6K 533 701
    ABBV PUT TRADE BULLISH 05/24/24 $162.50 $38.9K 1.1K 476
    IOVA PUT SWEEP BULLISH 01/17/25 $7.50 $31.3K 1.6K 296
    ISRG CALL TRADE NEUTRAL 06/28/24 $340.00 $60.9K 20 279
    BMY CALL TRADE BEARISH 01/16/26 $25.00 $67.6K 1.4K 215
    LLY CALL SWEEP BEARISH 06/21/24 $810.00 $138.7K 665 136
    MRNA PUT SWEEP BEARISH 10/18/24 $155.00 $35.6K 83 89
    HCA PUT SWEEP BEARISH 12/20/24 $300.00 $115.3K 52 83

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For PFE (NYSE:PFE), we notice a call option sweep that happens to be bullish, expiring in 7 day(s) on May 31, 2024. This event was a transfer of 2962 contract(s) at a $29.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $50.3K, with a price of $17.0 per contract. There were 6806 open contracts at this strike prior to today, and today 8214 contract(s) were bought and sold.

    • For SRPT (NASDAQ:SRPT), we notice a call option trade that happens to be bullish, expiring in 28 day(s) on June 21, 2024. This event was a transfer of 500 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $1.3 million, with a price of $2750.0 per contract. There were 211 open contracts at this strike prior to today, and today 1003 contract(s) were bought and sold.

    • For NVAX (NASDAQ:NVAX), we notice a call option sweep that happens to be bearish, expiring in 56 day(s) on July 19, 2024. This event was a transfer of 392 contract(s) at a $22.50 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $91.0 per contract. There were 533 open contracts at this strike prior to today, and today 701 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a put option trade that happens to be bullish, is expiring today. Parties traded 69 contract(s) at a $162.50 strike. The total cost received by the writing party (or parties) was $38.9K, with a price of $565.0 per contract. There were 1101 open contracts at this strike prior to today, and today 476 contract(s) were bought and sold.

    • For IOVA (NASDAQ:IOVA), we notice a put option sweep that happens to be bullish, expiring in 238 day(s) on January 17, 2025. This event was a transfer of 261 contract(s) at a $7.50 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $31.3K, with a price of $120.0 per contract. There were 1626 open contracts at this strike prior to today, and today 296 contract(s) were bought and sold.

    • For ISRG (NASDAQ:ISRG), we notice a call option trade that happens to be neutral, expiring in 35 day(s) on June 28, 2024. This event was a transfer of 9 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $60.9K, with a price of $6775.0 per contract. There were 20 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a call option trade with bearish sentiment. It expires in 602 day(s) on January 16, 2026. Parties traded 40 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $67.6K, with a price of $1690.0 per contract. There were 1469 open contracts at this strike prior to today, and today 215 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option sweep with bearish sentiment. It expires in 28 day(s) on June 21, 2024. Parties traded 60 contract(s) at a $810.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $138.7K, with a price of $2320.0 per contract. There were 665 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a put option sweep with bearish sentiment. It expires in 147 day(s) on October 18, 2024. Parties traded 26 contract(s) at a $155.00 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1370.0 per contract. There were 83 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold.

    • Regarding HCA (NYSE:HCA), we observe a put option sweep with bearish sentiment. It expires in 210 day(s) on December 20, 2024. Parties traded 83 contract(s) at a $300.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $115.3K, with a price of $1390.0 per contract. There were 52 open contracts at this strike prior to today, and today 83 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $BMY
    $HCA
    $IOVA

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    More analyst ratings

    $ABBV
    $BMY
    $HCA
    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Pfizer Inc.

    DEFA14A - PFIZER INC (0000078003) (Filer)

    3/12/26 9:12:24 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Pfizer Inc.

    DEF 14A - PFIZER INC (0000078003) (Filer)

    3/12/26 9:05:18 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 275 shares, decreasing direct ownership by 0.20% to 135,320 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/11/26 8:08:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Rothfuss Cristin covered exercise/tax liability with 830 shares, decreasing direct ownership by 0.60% to 138,518 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/11/26 8:07:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 1,399 shares, decreasing direct ownership by 0.61% to 226,271 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/11/26 8:04:04 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    92 HCA Healthcare Hospitals Earn Healthgrades Patient Safety Excellence Award

    HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that 92 of its hospitals achieved the 2026 Patient Safety Excellence Award from Healthgrades for their commitment to safe, patient-centered care. This recognition is given to the top 10% of hospitals nationwide for patient safety. "We are honored to be recognized, but even more proud of the work behind it," said Dr. Randy Fagin, senior vice president and chief quality officer of HCA Healthcare. "Learning from every patient and continuously strengthening the systems that help our caregivers deliver safe care, every day, is our commitment to earning and keeping the trust patients place in us."

    3/10/26 8:30:00 AM ET
    $HCA
    Hospital/Nursing Management
    Health Care

    AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

    ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels.  No serious adverse events were reported1Data support continued development of ABBV-295 as a potentially differentiated treatment for chronic weight management, with a non-incretin-based mechanism of action NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluati

    3/9/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

    Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE:BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will con

    3/9/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u

    3/2/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

    Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110.4 million of ELEVIDYS net product revenue Following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for

    2/25/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $HCA
    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care